Insider Selling: BioDelivery Sciences International, Inc. (BDSI) CFO Sells 16,161 Shares of Stock
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) CFO Paolantonio Ernest Robert De sold 16,161 shares of the firm’s stock in a transaction that occurred on Tuesday, December 4th. The shares were sold at an average price of $3.79, for a total transaction of $61,250.19. Following the transaction, the chief financial officer now directly owns 140,548 shares of the company’s stock, valued at approximately $532,676.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shares of BDSI opened at $3.63 on Friday. The company has a market cap of $260.20 million, a P/E ratio of -9.31 and a beta of 0.12. The company has a quick ratio of 2.77, a current ratio of 3.00 and a debt-to-equity ratio of 1.42. BioDelivery Sciences International, Inc. has a twelve month low of $1.70 and a twelve month high of $4.14.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.04. The company had revenue of $14.16 million during the quarter, compared to the consensus estimate of $14.21 million. BioDelivery Sciences International had a negative net margin of 85.93% and a negative return on equity of 141.35%. On average, sell-side analysts anticipate that BioDelivery Sciences International, Inc. will post -0.61 EPS for the current fiscal year.
A number of equities analysts have weighed in on BDSI shares. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of BioDelivery Sciences International in a research note on Friday, August 10th. Zacks Investment Research raised shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a research note on Wednesday, October 3rd. Cantor Fitzgerald set a $5.00 target price on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research note on Sunday, October 7th. Janney Montgomery Scott raised their price target on shares of BioDelivery Sciences International to $5.00 and gave the company a “buy” rating in a research report on Friday, November 2nd. Finally, BidaskClub downgraded shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Tuesday, November 13th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $4.54.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
See Also: Return on Investment (ROI)
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.